and Impax Laboratories LLC escaped the Federal Trade Commission’s appeal of a lawsuit alleging the companies’ agreement over the use of an extended-release painkiller violated antitrust law.Ī panel of US Court of Appeals for the D.C. Negotiations for this settlement were led by Pennsylvania with Maine, Massachusetts, New Hampshire, Tennessee, Vermont, and Virginia.Endo Pharmaceuticals Inc. Bans the marketing of Endo’s opioids forever.Requires Endo to turn over its opioid-related documents for publication online in a public document archive and pay $2.75 million for archival expenses.Requires payment of $450 million in cash over 10 years to participating states and subdivisions.The resolution, which is contingent on final documentation and Bankruptcy Court approval, involves the following: That investigation has led to, including today’s settlement, $40.85 billion in settlement agreements with opioid manufacturers and distributors. This agreement is the result of a multistate investigation, led by Attorney General Shapiro, into six manufacturers and three distributors for their roles in the opioids epidemic. The states allege that Endo falsely promoted the benefits of Opana ER’s so-called abuse-deterrent formulation, which did nothing to deter oral abuse and led to deadly outbreaks of Hepatitis and HIV due to its widespread abuse via injection. headquarters in Malvern, Pennsylvania and makes generic and branded opioids including Percocet and Endocet and also made Opana ER, which was withdrawn from the market in 2017. Today’s agreement in principle with Endo, which filed for Chapter 11 bankruptcy protection Monday night in the Southern District of New York, stems from allegations that Endo boosted opioid sales using deceptive marketing that downplayed the risk of addiction and overstated the benefits of opioids. Nothing will make up for the lives lost to this crisis, but today’s agreement will help to ensure we can fund programs Pennsylvania communities need to recover from this crisis.” “Endo downplayed the risk of addiction, going so far as to market one of their opioids as having an abuse-deterrent formula, when in reality the product did nothing to deter abuse. “Every company that fueled this deadly epidemic will answer for their reckless actions,” said AG Shapiro. Once finalized, the Endo settlement would provide as much as $450 million nationwide to communities hit hardest by the opioid epidemic. ![]() The multistate agreement would provide up to $450 million to participating states and local governments, ban promotion of Endo’s opioids, and require Endo to turn over millions of documents related to its role in the opioid crisis for publication in a public online archive.ĪG Shapiro and the Pennsylvania Office of Attorney General have investigated several opioid distributors and manufacturers in an effort to hold pharmaceutical companies accountable, including Purdue, McKinsey, Teva, and others, for jet-fueling the opioid epidemic we continue to battle. HARRISBURG– Attorney General Josh Shapiro today announced his office has reached an agreement in principle with opioid manufacturer Endo International and its lenders. ![]() Proposed national settlement would provide funding to address opioid crisis, require significant document disclosure, and ban the promotion of Endo’s opioids
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |